Literature DB >> 6992701

Drug pharmacokinetics in cardiac and hepatic disease.

R L Williams, L Z Benet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6992701     DOI： 10.1146/annurev.pa.20.040180.002133

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN： 0362-1642            Impact factor:   13.820


× No keyword cloud information.
  10 in total

1.  Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis.

Authors:  F Albani; M R Tamè; R De Palma; M Bernardi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Drug-binding proteins in liver transplant patients.

Authors:  M L Huang; R Venkataramanan; G J Burckart; R J Ptachcinski; D H Van Thiel; T E Starzl
Journal:  J Clin Pharmacol       Date:  1988-06       Impact factor: 3.126

Review 3.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  Formal theory of discrete drug dosing regimen adjustments.

Authors:  I Janků
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.

Authors:  M Eichelbaum; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Hemodynamic influences upon the variance of disposition residence time distribution of drugs.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Authors:  P M Wilkinson; P A O'Neill; N Thatcher; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.

Authors:  M Láznícek; K E Senius
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.

Authors:  Reiner Frey; Corina Becker; Soundos Saleh; Sigrun Unger; Dorina van der Mey; Wolfgang Mück
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.